Source comparison
CJC-1295 Bioavailability: Form Comparison
Plasma Half-Life 7–10 minutes 6–8 days DAC modification is required for sustained systemic exposure. Unmodified form is unsuitable for multi-day protocols Peak Plasma Concentration (Cmax) High (2–3× DAC form) Moderate (sustained) Higher peak does not equal bet
This comparison does not assign a generated winner or score.
- Plasma Half-Life
- 7–10 minutes
- 6–8 days
- DAC modification is required for sustained systemic exposure. Unmodified form is unsuitable for multi-day protocols
- Peak Plasma Concentration (Cmax)
- High (2–3× DAC form)
- Moderate (sustained)
- Higher peak does not equal better efficacy. Receptor desensitisation negates bolus advantage in long-term studies
- Dosing Frequency
- 2–3× daily
- 1× weekly or less
- Unmodified form requires frequent administration due to rapid enzymatic degradation
- Primary Degradation Pathway
- DPP-IV cleavage at N-terminus
- Albumin binding protects from enzymatic degradation
- Steric hindrance from albumin-peptide complex prevents DPP-IV and NEP access
- Renal Clearance
- Rapid (free peptide filtered within 20 min)
- Minimal (albumin complex too large for glomerular filtration)
- DAC form's extended half-life is largely due to reduced renal elimination
- Research Application
- Acute GH pulse studies, circadian rhythm models
- Sustained anabolic signaling, tissue regeneration, metabolic studies
- Match molecular form to research question. This is non-negotiable